One-Step Antibody-Drug Conjugate Synthesis via pH-Controlled Crosslinking
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Conventional methods for producing antibody-drug conjugates (ADCs) are complex and result in products of lower purity and stability due to cumbersome manufacturing steps.
Innovation Solution
A one-step process involving direct contact of a cell-binding agent with a cytotoxic agent, followed by a bifunctional crosslinking reagent in a pH-controlled solution, to form a cell-binding agent cytotoxic agent conjugate, with subsequent purification to achieve high purity and stability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If conventional two-step conjugation method is used, then the antibody can be modified with linker and subsequently conjugated with cytotoxic agent, but the process becomes complex with cumbersome steps and reduced product purity and stability
Solution Approach 1:
The patent combines the linker modification step and the cytotoxic agent conjugation step into a single simultaneous reaction step. The antibody, linker, and cytotoxic agent are all present in the reaction mixture at the same time, allowing the conjugation to occur in one step rather than requiring sequential two-step processing. This merging of steps simplifies the overall process while maintaining or improving conjugate purity.
2Productivity
If conventional two-step conjugation method is used, then the antibody can be modified and purified, but the process requires additional purification steps and increases manufacturing time
Solution Approach 1:
The patent merges multiple manufacturing operations into a single reaction vessel and time frame. The antibody modification and cytotoxic agent conjugation occur simultaneously, eliminating the need for intermediate purification steps between steps. This significantly reduces manufacturing time and improves overall productivity.
Solution Approach 2:
The patent employs preliminary activation of the linker to form a reactive intermediate that can directly react with the cytotoxic agent in the same reaction mixture. This preliminary action prepares the conjugation interface in advance, allowing the actual conjugation to proceed efficiently without requiring separate purification and re-suspension steps.
3Stability of the object's composition
If conventional two-step conjugation method is used, then the antibody can be conjugated with cytotoxic agent, but the process produces lower stability conjugates
Solution Approach 1:
The patent combines all conjugation components in a single reaction system, allowing for optimized reaction conditions that promote stable conjugate formation. The simultaneous presence of antibody, linker, and cytotoxic agent enables proper stoichiometric control and reaction kinetics that enhance conjugate stability compared to sequential methods.
Solution Approach 2:
The patent optimizes reaction parameters such as pH, temperature, and reagent concentrations to favor the formation of stable conjugates. By controlling these parameters in the single-step process, the method achieves higher conjugate stability while simplifying the overall procedure.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The process simplifies the production of ADCs, enhancing their purity and stability, reducing time and cost while maintaining effective conjugation efficiency.
Implementation Method 1
contacting the first mixture comprising the cell-binding agent and the cytotoxic agent with a bifunctional crosslinking reagent comprising a linker, in a solution having a pH of about 4 to about 9 to provide a mixture comprising (i) the cell-binding agent cytotoxic agent conjugate, wherein the cell-binding agent is chemically coupled through the linker to the cytotoxic agent
Data Source
AI summary
The invention provides a one-step process for preparing a cell-binding agent cytotoxic agent conjugate comprising contacting a cell-binding agent with a cytotoxic agent to form a first mixture comprising the cell-binding agent and the cytotoxic agent and contacting the first mixture comprising the cell-binding agent and the cytotoxic agent with a bifunctional crosslinking reagent, which provides a linker, in a solution having a pH of about 4 to about 9 to provide a second mixture comprising the cell-binding agent cytotoxic agent conjugate, wherein the cell-binding agent is chemically coupled through the linker to the cytotoxic agent, free cytotoxic agent, and reaction by-products. The second mixture is then optionally subjected to purification to provide a purified cell-binding agent cytotoxic agent conjugate.